Tonic pain perception mouse differential modulation receptor-selective opioid agonists proposition tonic nociception models analogous clinical pain traditional acute models previous development mouse paw formalin test possible modulatory roles site action endogenous opioid systems receptor-preferring agonists mu kappa enkephalin DPDPE delta antinociceptive activity formalin paradigm systemic DPDPE spinal supraspinal routes observations blind conditions overt behaviors breach receptor specificity observation period doses DPDPE micrograms/mouse intrathecal micrograms/mouse intracerebroventricular behavioral syndrome mu agonism study acceptable dose ranges mean percent analgesia reduction paw controls trans- cyclohexyl -benzeneacetamide methanesulfonate nmol/kg subcutaneous nmol/kg intrathecal nmol/kg intracerebroventricular sufentanil nmol/kg subcutaneous nmol/kg intrathecal DPDPE inactive basis dose-response data mice kappa mu delta opioid receptors tonic pain perception spinal supraspinal loci results inclusion modified formalin test preclinical evaluations potential kappa agonists 